Clinical trial · Observational
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
Induction Chemotherapy, Chemo-radiotherapy and Surgery in Locally Advanced Gastric Cancer Patients: Long Term Results From a Single Institution.
NCT02454647CI-TRIAL-00018068completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the efficacy of a neoadjuvant approach in patients with locally advanced gastric cancer and the identification of prognostic factors.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Effects of Chemotherapy | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastrointestinal Neoplasms | Digestive System Neoplasm | ALIAS | 0.90 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Induction chemotherapy | Drug | — | UNRESOLVED |
| Radiotherapy with concurrent chemotherapy | Radiation | — | UNRESOLVED |
| Salvage surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Overall Survival
- timeFrame
- From date of treatment until death, assessed up to 10 years
- description
- Overall was defined as the period from diagnosis until death (from any cause).
- measure
- Identification of prognostic factors for overall survival
- timeFrame
- From date of treatment until death, assessed up to 10 years
- description
- Overall was defined as the period from diagnosis until death (from any cause). Correlation between survival and baseline, clinical and treatment characteristics from patients
- measure
- Disease-free survival
- timeFrame
- From date of diagnosis until progression or death, assessed up to 10 years
- description
- Disease-free survival was defined as the time from diagnosis to the first date of local or distant cancer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the stomach * Age ≥18 years old * Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 * Body mass index ≥ 18 * No prior chemotherapy or chemoradiotherapy * TNM stage of T3-T4 and/or positive regional lymph nodes (N+) by endoscopic ultrasound or computed tomography (CT) * No evidence of metastasis (M0) * Adequate hematological, liver and renal functions (ALT and AST≤2.5 UNL, total bilirubin ≤1.5 UNL, and serum creatinine ≤1.5 UNL) Exclusion Criteria: * Patients with previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated * Patients with evidence of severe or uncontrolled systemic disease * Medically unfit for chemotherapy * Tumors involving the esophageal junction, comprising siewert I to III
References
Publications (0)
Data not yet available
No reference posted for this study.